FY2025 · ended Dec 31, 2025 · Revenue $893,000, +1075.0% YoY · Filed Mar 18, 2026
Prokidney Corp. (PROK) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $893,000 and a net loss of $69.0 million. Free cash flow was -$135.3 million. As of Jun 30, 2026 it held $210.0 million in cash and investments and $3.5 million in total debt.
Revenue (TTM)
$818,000
Net income (TTM)
$-84.16M
-16.1% vs year-ago TTM
Operating cash flow (TTM)
$-141.17M
-23.4% vs year-ago TTM
Free cash flow (TTM)
$-159.73M
-9.0% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$206.47M
as of Jun 30, 2026
Operating margin
-21664.5%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PROK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Winston-Salem, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1850270
- Former names
- Social Capital Suvretta Holdings Corp. III (until Jul 11, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|
| Revenue | $893,000 | $76,000 | — | — |
| Operating income | -$165.0M | -$183.7M | -$151.5M | -$55.1M |
| Net income | -$69.0M | -$61.2M | -$35.5M | -$55.1M |
| Operating cash flow | -$120.1M | -$126.4M | -$90.1M | -$50.3M |
| Free cash flow | -$135.3M | -$155.9M | -$124.3M | — |
| Total assets | $335.6M | $441.1M | $420.6M | $40.3M |
| Total liabilities | $34.8M | $39.4M | $29.2M | $13.4M |
| Stockholders' equity | -$1.0B | -$995.0M | -$1.1B | $26.9M |
| Cash and investments | $310.5M | $358.3M | $362.9M | $20.6M |
| Total debt | $4.0M | $3.2M | $4.4M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 28, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
May 15, 2026 | May 15, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
All 401 Prokidney Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.